Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 27, 2026.

New Insights in Glucocorticoid Receptor Signaling—More Than Just a Ligand-Binding Receptor

Karin Scheschowitsch, Jacqueline Alves Leite, Jamil Assreuy

Frontiers in Endocrinology · 2017 · Review

doi:10.3389/fendo.2017.00016

Abstract

The clinical use of classical glucocorticoids (GC) is narrowed by the many side effects it causes and the resistance to GC observed in some diseases. Since the great majority of GC effects depend on the activation of a glucocorticoid receptor (GR), many research groups had focused to better understand the signaling pathways involving those receptors. Transgenic animal models and genetic modifications of the receptor brought a huge insight into GR mechanisms of action. This in turn opened a new window for the search of selective GR modulators that ideally may have agonistic and antagonistic combined effects and activate one specific signaling pathway, inducing mostly transrepression or transactivation mechanisms. Another important research field concerns to posttranslational modifications that affect the GR and consequently also affect its signaling and function. In this mini review, we discuss many of those aspects of GR signaling, as well as findings like the ligand-independent activation of GR, which add another layer of complexity in GR signaling pathways. Although several recent data have been added to the GR field, much work has yet to be done, especially to find out the biological relevance of those alternative GR signaling pathways. Improving the knowledge about alternative GR signaling pathways and understanding how these pathways intercommunicate and in which situations they are relevant might help to develop new strategies to take benefit of it and to improve GC or other compounds efficacy causing minimal side effects.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 27, 2026. Paragraph numbers are ours, so an answer can point at one.

Importance of Glucocorticoids (GC) in Controlling Inflammation

Glucocorticoids (cortisol in humans and corticosterone in rodents) are steroid hormones [revised in Ref.] involved in several physiological functions and in controlling inflammation. From their discovery until the present day, GC are considered the most effective anti-inflammatory drugs and one of the most widely prescribed drug classes worldwide.

Despite their potent anti-inflammatory effects, steroids cause relevant side effects when used for longer periods and at high doses, limiting their use and reducing adherence to treatment. Therefore, understanding the signaling mechanisms and pathways related to GC and their receptor [glucocorticoid receptor (GR)] is essential to provide the basis for the development of new selective glucocorticoid receptor modulators (SEGRMs). SEGRMs are expected to present the same or better efficacy compared to classical steroids, but causing minimal side effects. The present mini review will discuss advances in GR signaling pathways looking for a better comprehension about the beneficial and harmful effects of endogenous and exogenous GC, especially in inflammation.

The GR

The main actions of GC occur through the activation of GRs (NR3C1), which are transcription factors (TFs) belonging to the superfamily of nuclear receptors and are usually activated by ligands. GR is composed of three major functional domains, namely the N-terminal transactivation domain (NTD), the central DNA-binding domain (DBD), and the C-terminal ligand-binding domain (LBD). In the absence of ligands, GR is predominantly found in the cytoplasm complexed with accessory proteins (hsp90, hsp70, hsp56, p23, and immunophilins) and is kept in a conformation of high-binding affinity to GC (see Figure 1: 1). GR can actively shuttle between cytoplasm and nucleus, being the balance rate of nuclear import and export which determines the receptor cellular location. Increases in receptor density affect its conformation and location and may cause ligand-free dimerization that facilitates the subsequent binding of ligands, thus bypassing dimerization-dependent mechanisms of action.

One of the first proposed signaling pathways for GR was that the binding of a ligand to the LBD of monomeric GR would induce its nuclear localization sequence (NLS) exposure. Then, accessory proteins would dissociate from the monomeric receptor, allowing it to dimerize and translocate along microtubules to the nucleus. There, GR dimers would bind to DNA through their DBD to exert their effects.

Further evidence showed that ligand binding triggers NLS exposure due to the replacement of immunophilin FKBP51 by FKBP52, which interacts with dynein, carrying the whole monomeric GR complex along microtubules to a nuclear pore. FKBP52 also facilitates the entry of GR monomeric complex into the nucleus, as well as exporting the accessory proteins back to the cytoplasm via importins (see Figure 1: 1). Once in the nucleus, monomeric GR can assume different conformations depending on the glucocorticoid-responsive elements (GREs). GR monomer can recruit another monomer to form a GR homodimer on DNA, through distinct hydrophobic motifs of the LBD. Nevertheless, the subcellular compartment for GR dimerization is still in debate, and the GR binding regions used by specific GREs are still unclear. Therefore, more studies aiming to create predictive models for GR activity may help the development of new compounds.

Regarding GR nuclear translocation, it is suggested that different ligands can induce the exposure of one of the two so far described NLS for GR, influencing its nuclear translocation speed. Classical GR ligands are suggested to induce NLS-1 exposure, which interacts with importins and nucleoporins, leading to rapid nuclear translocation (within 4–6 min). Shuttling of unliganded GR depends on NLS-1 interaction with importin-alpha. On the other hand, NLS-2 exposure is strictly ligand dependent and mediates slower GR nuclear translocation (45 min–1 h).

Transgenic Animal Models

Since GR was cloned, the development of animals and cells with full or partial GR depletion and with different GR mutations allowed the study of the role of GR. The first GR knockout mice (GRnull) presented severe lung developmental abnormalities and died shortly after birth. On the other hand, animals that overexpress GR are resistant to septic shock. Organ-specific GR depletion have shown that (a) hepatic GR is responsible for gluconeogenesis and production of postnatal insulin-like growth factor-1; (b) GR depletion in the central nervous system leads to numerous behavioral abnormalities; (c) mice with specific depletion of GR in macrophages, neutrophils, or endothelial cells are more sensitive to pro-inflammatory stimuli, evidencing the important role for GR in these cells for the physiological control of inflammation.

Development of a mutation in the second zinc finger of DBD (called GRdim) prevented GR homodimerization on most tandem GREs. Notwithstanding that this mutation strongly attenuates GR dimerization and impairs GR transcription activity from tandem GREs, it does not completely abrogate transactivation mechanisms, since it was recently discovered that it depends on promoter contexts. Furthermore, DNA motifs specify the genomic occupancy of monomeric GR and interfere with the availability of GR dimers binding sites. However, unlike GRnull mice, GRdim animals are viable and normal with respect to the major physiological GR-mediated functions, although more susceptible to inflammation. In a model of antigen-induced arthritis using GRdim mice, it was shown that GR dimerization is necessary for the anti-inflammatory effects of GC by suppressing Th1 and Th17 cells activity. Considering other GR mutations, it was observed that (a) heterozygous GR knockout mice, in which GR expression is reduced by half, were less sensitive to dexamethasone therapy in experimental autoimmune encephalomyelitis; (b) mice with selective GR depletion in T cells (GRlck-Cre) succumb to toxoplasma infection due to increased TNF and IFN-γ production by Th1 cells; and (c) mice with selective GR depletion in the thymocytes showed loss of the adaptive immune response and were immunocompromised.

GR-Mediated Mechanisms of Action

Glucocorticoid effects usually depend on its interaction with GR in the cytoplasm to trigger a variety of cell responses that culminate in several changes in the whole body. Although most cells have similar GC response machineries, steroids exhibit varied effects in different tissues. This might be attributed to GR ubiquitous expression (except in red blood cells), to the numerous mechanisms that alter its function, and to the enormous assortment of GR-binding sites and their availability. Binding site availability depends on chromatin state, which is specific for each tissue and cell type. Also, GC concentration may determine which GREs are occupied by GR. Therefore, chromatin accessibility and GREs distinct sensitivity also help to explain why GC trigger different effects in different tissues. By using different chromatin immunoprecipitation sequencing, it was shown that C/EBPβ maintains chromatin accessibility to facilitate selective GR binding to GREs in liver tissue, another evidence of cell type-specific GR-induced transcription. Intracellular GR location, interaction with other proteins, binding capacity and sensitivity to GC and other modulators, receptor degradation rate, and intracellular density directly interfere with GC efficacy. Finally, the effects triggered by the GC-GR complex are tissue and cell type dependent and vary with the posttranslational modifications that will affect the receptor according to the host condition.

The classical mechanism of action of nuclear receptors involves gene transcription (transactivation) or direct or indirect impairment of transcription of other TFs (transrepression) (Figure 1: 2). Currently, the most accepted transactivation model involves GR dimerization after binding of GC-GR monomeric complexes to GREs (see Figure 1A). This induces GR conformational changes to recruit cofactors, like histone acetyl transferases and C/EBPβ, that change the chromatin state facilitating gene expression. The type of dimer that will be formed and which cofactors will be recruited seem to be determined by the gene sequence in question. Interestingly, it was recently shown that monomeric GR interacts with a half-site motif and drives transcription (see Figure 1E) in liver and primary macrophages, being more prevalent than homodimer binding under physiological conditions and being essential for those tissue-specific functions. Exogenous GC appear to favor gene expression by the binding of GR homodimers and disruption of GR monomeric binding from their half-site motifs. This discovery calls for a revision of transactivation mechanisms and other possible transrepression mechanisms involving monomeric GR binding to half-sites (Figures 1B–E).

Protein–protein interaction of GR with other TFs is an important mechanism of direct transrepression known as tethering mechanism. Monomeric GR can crosstalk with another TF (Figure 1F) or directly interact with critical points of TFs before they bind to its responsive element on DNA (Figure 1J). In this case, best exemplified for the nuclear transcription factor kappa-B (NF-κB), interaction may occur in the cytoplasm, preventing NF-κB activation and its nuclear translocation, or in the nucleus, impairing DNA NF-κB-binding capacity. Nonetheless, GR monomers can also repress TFs even if they are already bound to DNA (see Figures 1H,I) and can compete for an overlapping binding site (Figure 1G). Therefore, GR can regulate the expression of different TFs such as NF-κB, AP-1, STATs, Oct, NF-1, C/EBP, COUP-TFII, PPARs, and LXR.

Glucocorticoid receptor binding to DNA can also suppress gene expression by interacting with novel described negative GREs (nGREs). Recently, an extensive conserved family of negative palindromic GREs (IR nGREs) was found to form a repressing complex through association of SMRT/NCoR corepressors and HDACs, mediating transrepression by the direct binding of agonist-bound GR. Evidence showed that two GR monomers can bind to nGREs with inverted polarity if compared on how they bind to GREs (Figure 1L). This kind of monomer binding induce a unique conformational change that, together to the recruitment of corepressors, guarantee the presence of single monomers of GR bound to nGREs. As nGREs are near to responsive elements of other TFs, that binding can allosterically prevent the binding of other factors to DNA and recruit corepressors (see Figure 1K).

Indirect modes of reducing gene expression involve GC-induced expression of inhibitory proteins such as glucocorticoid-induced leucine zipper (GILZ) protein via modulation of MAPK pathways. GILZ protein binds to the p65 subunit of NF-κB in T-cells and macrophages, impairing gene transcription and suppressing inflammation. In addition, Lethe, a pseudogene non-coding RNAs induced by cytokines (IL-1β, TNF-α) and GC, might be involved in the negative feedback NF-κB signaling to control inflammation.

Since it was believed that GC side effects occur through transactivation mechanism, researchers became interested in identifying SGRMs to enhance GC therapeutic effects with fewer side effects. Compound A (CpdA) is a non-steroidal ligand analog that binds GR with high affinity and induces its nuclear translocation. However, it mostly triggers transrepression tethering mechanisms with NF-κB and/or binding to nGREs, while inhibiting GR dimerization and preventing dimerization-dependent side effects such as hyperglycemia. GR unique conformation upon CpdA binding may impair receptor phosphorylation, which is the suggested mechanism why CpdA does not induce GC resistance and maintain its efficacy even after long periods of administration. Unfortunately, CpdA also present a limited therapeutic window due to its toxic effects in higher concentrations. In vitro studies with CpdX, a novel SEGRM, demonstrated that it is efficient in decreasing inflammation through tethering mechanism, albeit not inducing GRE transactivation and IR nGRE transrepression. In vivo studies are necessary to reveal the clinical value of CpdX. Compound C108297 presents agonistic and antagonistic properties in the rat brain and can simultaneously prevent diet-induced obesity and inflammation. Although promising, it is still unclear whether C108297 is an antagonist or a partial agonist and if it induces a unique conformational of the GR-LBD or a two-state agonist conformation. Therefore, more studies are needed to better understand the signaling pathways involved in C108297 effects. Moreover, since new evidence suggests that those agonists or modulators do not necessarily need to be a GR ligand, SEGRMs concept is still in debate.

GR Isoforms and Posttranslational Modifications

There are two major GR isoforms that differ only in their C-terminal regions, GRα and GRβ (subtypes of each isoform and other isoforms will not be discussed due to space limitation). The DBD is conserved across the nuclear receptor family and consists of two zinc fingers motifs important to GR dimerization and tandem GRE binding. GRα is the classic receptor responsible for GC actions, whereas GRβ does not bind GC and its biological relevance is still uncertain. It has been suggested that GRβ acts as a negative regulator of GRα isoform (see Figure 1M), because it can bind to GREs but does not induce its transcription. GRβ has an intrinsic transcriptional activity in non-GC-regulated genes. Recently, a pro-inflammatory role for GRβ was shown in the liver tissue of obese mice, suggesting that steatosis correlates to GRβ increased expression in adipose and liver tissues. The same study showed that GRβ antagonizes GC-induced signaling through GRα during fasting. So far, this is the first study showing a pro-inflammatory role for GRβ. More studies should focus in unveiling the biological relevance of GRβ in other tissues and cofactors of its singular signaling pathway.

Several posttranslational modifications also play an important role in enhancing or decreasing GR functionality to confer distinct biological functions (see Figure 1: 6). Examples include phosphorylation, acetylation, ubiquitination, methylation, nitrosylation, nitration, and SUMOylation [revised in Ref.]. Due to space limitations, we will focus on recent data about some of them. Nitrosylation of specific cysteine residues decreases GR binding capacity and increases resistance to GC action, while tyrosine nitration residues favor nuclear translocation and receptor activity. However, exogenous NO seems to activate the endothelial cell GR. NO effects very much depend on its concentration and compartmentalization, and this is probably the reason for divergent results. Regarding to SUMOylation, it is related to stabilization, location, and transcriptional activity of GR, typically increasing it. However, recent reports demonstrated that SUMOylation is mandatory for GC-dependent transrepression mediated by IR nGREs. SUMOylation of GR lysine residues (mouse: K310 and human: K293) within the NTD is essential for the assembly of the repressive complex SMRT/NCoR-1-HDAC3. The same SUMOylation site is essential for the tethering transrepression mechanism mediated by NF-κB/AP-1, which needs the formation of a GR small ubiquitin-related modifiers (SUMOs)–SMRT/NCoR1-HDAC3 repressing complex.

Ligand-Independent Activation of GR

Beyond the consensus that steroidal or analog binding induces GR nuclear translocation, several evidences have shown that GR can be activated in the absence of ligands. Sodium arsenite and dinitrophenol, some conditions such as elevated pH and temperature, and shear stress can induce GR nuclear translocation in a ligand-independent manner (Figure 1: 1). Interestingly, GR nuclear translocation induced by shear stress does not depend on ligands or intact cytoskeleton, but it is related to the nuclear lamina.

Unliganded GR acts as a positive regulator of the tumor suppressor gene BRCA1. This beneficial effect is lost upon addition of ligand, suggesting unliganded GR displacement from BRCA1 promoter in response to steroids decreases BRCA1 expression and increases the risk for breast cancer. That fact might be related to endogenous monomeric GR binding to half-site motifs, as already discussed. Transient transfection and GR overexpression in GR-deficient cells (COS-1) induced nuclear GR dimerization, GR binding to DNA, and transcription in the absence of exogenous GC (see Figures 1: 1 and 2). Moreover, TNF-α can induce ligand-independent activation of GR pathways in COS-1 and epithelial cells, leading to decreased levels of IL-6 and IL-8. However, the mechanisms of ligand-independent GR activation are not completely understood. One report suggests that GR phosphorylation at Ser-211 is enough for ligand-independent activation, whereas another report suggests that phosphorylation at Ser-134 also can induce ligand-independent GR nuclear translocation as part of the cellular stress pathway, but other mechanisms might be involved.

Non-Genomic Mechanisms of Action

Several GC effects occur within a few seconds or minutes after administration, evidencing a non-genomic mechanism of action. This mechanism is particularly important in the vascular system and in dampening inflammation and usually involves activation of non-cytoplasmic GR or even GR-independent pathways (see Figures 1: 3 and 4). Nevertheless, activation of cytoplasmic GR cannot be excluded.

Membrane-bound receptors (mGR) have distinct properties if compared to cytoplasmic GR and are more related to intracellular signaling pathways mediated by G-protein-coupled receptors. Although some studies suggest that mGR is a GRα isoform, others claim that it is in fact a GRγ isoform (Figure 1: 3). Importantly, high doses of GC can act independently of GR by increasing second messengers, such as inositol-3-phosphate, cyclic adenosine monophosphate, and calcium ion (Figure 1: 4). The presence of GR in human mitochondria and similar GRE sequences in mitochondrial DNA were identified long time ago. Moreover, direct GC-stimulated mitochondrial transcription mediated by mitochondrial GR was also demonstrated in hepatocarcinoma cells. It was recently suggested that GRγ isoform resides in mitochondria and is related to cell energy metabolism regulation in a ligand-independent manner (see Figure 1: 5).

Protein–protein interaction between ligand-activated GR and the regulatory subunit (p85α) of phosphoinositol-3-kinase in endothelial cells activates the protein kinase Akt, which phosphorylates and activates NO synthase-3. This mechanism would explain the rapid and transient cardiovascular protective effect of high GC doses in myocardial emergencies. A rapid decrease in peripheral resistance and blood pressure is observed minutes after GC administration, accompanied by an increase in coronary and cerebral blood flows. Since rapid vasoconstriction and changes in bronchial blood flow are observed few seconds after inhaled GC administration in asthmatic attacks, it suggests that non-genomic effects also may vary according to the tissue. Furthermore, endothelial cell stimulation with dexamethasone rapidly activates ERK and kinase c-Jun N-terminal MAPK to produce reactive oxygen species and activate TFs.

Summary and Future Directions

In summary, recent data have added new layers of complexity to GR signaling pathways. Clearly GR signaling does not depend only on ligand binding, and its classical mechanisms of action need further revision. Given the physiological and clinical importance of GC and their side effects, it is essential to further investigate alternative GR signaling pathways and their respective biological relevance. This might help to develop new strategies to take benefit of it as well as to improve GC or analogs efficacy with minimal side effects.

Author Contributions

KS and JA discussed the structure of the manuscript. KS wrote the initial draft and created the figure. KS and JL worked to finish the revised manuscript, and JA did the final review prior to submission. KS, JL, and JA exchanged several revisions until the final manuscript was agreed upon all the authors.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 126

  1. 1.

    Sundahl N Bridelance J Libert C De Bosscher K Beck IM. Selective glucocorticoid receptor modulation: new directions with non-steroidal scaffolds. Pharmacol Ther (2015 ) 152:28–41.

    Not in our library10.1016/j.pharmthera.2015.05.001

  2. 2.

    Sapolsky RM Romero LM Munck AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev (2000 ) 21:55–89.

    Not in our library10.1210/er.21.1.55

  3. 3.

    Meir Drexler S Wolf OT. The role of glucocorticoids in emotional memory reconsolidation. Neurobiol Learn Mem (2016 ).

    Not in our library10.1016/j.nlm.2016.11.008

  4. 4.

    Baschant U Tuckermann J. The role of the glucocorticoid receptor in inflammation and immunity. J Steroid Biochem Mol Biol (2010 ) 120:69–75.

    Not in our library10.1016/j.jsbmb.2010.03.058

  5. 5.

    Silverman MN Sternberg EM. Glucocorticoid regulation of inflammation and its functional correlates: from HPA axis to glucocorticoid receptor dysfunction. Ann N Y Acad Sci (2012 ) 1261:55–63.

    Not in our library10.1111/j.1749-6632.2012.06633.x

  6. 6.

    Heitzer MD Wolf IM Sanchez ER Witchel SF DeFranco DB. Glucocorticoid receptor physiology. Rev Endocr Metab Disord (2007 ) 8:321–30.

    Not in our library10.1007/s11154-007-9059-8

  7. 7.

    Erhuma AM Glucocorticoids: biochemical group that play key role in fetal programming of adult disease. In: Qian X, editor. Glucocorticoids – New Recognition of Our Familiar Friend. Rijeka: InTech (2012 ). p. 449–78.

    Not in our library

  8. 8.

    De Bosscher K Haegeman G. Minireview: latest perspectives on antiinflammatory actions of glucocorticoids. Mol Endocrinol (2009 ) 23:281–91.

    Not in our library10.1210/me.2008-0283

  9. 9.

    Bijlsma JWJ Jacobs JWG Buttgereit F. Glucocorticoids in the treatment of rheumatoid arthritis. Clin Exp Rheumatol (2015 ) 33(4 Suppl 92):S34–6.

    Not in our library

  10. 10.

    Dibas A Yorio T. Glucocorticoid therapy and ocular hypertension. Eur J Pharmacol (2016 ) 787:57–71.

    Not in our library10.1016/j.ejphar.2016.06.018

  11. 11.

    Hakim A Usmani OS. Enhancing nuclear translocation: perspectives in inhaled corticosteroid therapy. Ther Deliv (2015 ) 6:443–51.

    Not in our library10.4155/tde.15.10

  12. 12.

    Normansell R Kew KM Mansour G. Different oral corticosteroid regimens for acute asthma. Cochrane Database Syst Rev (2016 ) (5):CD011801.

    Not in our library10.1002/14651858.cd011801.pub2

  13. 13.

    Ortsäter H Sjöholm Å Rafacho A Regulation of glucocorticoid receptor signaling and the diabetogenic effects of glucocorticoid excess. State of the Art of Therapeutic Endocrinology. Rijeka: InTech (2012 ). p. 1–28.

    Not in our library

  14. 14.

    Beck IM De Bosscher K Haegeman G. Glucocorticoid receptor mutants: man-made tools for functional research. Trends Endocrinol Metab (2011 ) 22:295–310.

    Not in our library10.1016/j.tem.2011.03.009

  15. 15.

    Huscher D Thiele K Gromnica-Ihle E Hein G Demary W Dreher R Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis (2009 ) 68:1119–24.

    Not in our library10.1136/ard.2008.092163

  16. 16.

    Ayroldi E Riccardi C. Glucocorticoid-induced leucine zipper (GILZ): a new important mediator of glucocorticoid action. FASEB J (2009 ) 23:3649–58.

    Not in our library10.1096/fj.09-134684

  17. 17.

    Rosen J Miner JN. The search for safer glucocorticoid receptor ligands. Endocr Rev (2005 ) 26:452–64.

    Not in our library10.1210/er.2005-0002

  18. 18.

    De Bosscher K. Selective glucocorticoid receptor modulators. J Steroid Biochem Mol Biol (2010 ) 120:96–104.

    Not in our library10.1016/j.jsbmb.2010.02.027

  19. 19.

    Duma D Jewell CM Cidlowski JA. Multiple glucocorticoid receptor isoforms and mechanisms of post-translational modification. J Steroid Biochem Mol Biol (2006 ) 102:11–21.

    Not in our library10.1016/j.jsbmb.2006.09.009

  20. 20.

    Löwenberg M Stahn C Hommes DW Buttgereit F. Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands. Steroids (2008 ) 73:1025–9.

    Not in our library10.1016/j.steroids.2007.12.002

  21. 21.

    Vandevyver S Dejager L Tuckermann J Libert C. New insights into the anti-inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid-receptor-mediated transactivation. Endocrinology (2013 ) 154:993–1007.

    Not in our library10.1210/en.2012-2045

  22. 22.

    Smoak KA Cidlowski JA Mechanisms of glucocorticoid receptor signaling during inflammation. Mech Ageing Dev (2004 ) 125:697–706.

    Not in our library10.1016/j.mad.2004.06.010

  23. 23.

    Kumar R Thompson EB. Gene regulation by the glucocorticoid receptor: structure:function relationship. J Steroid Biochem Mol Biol (2005 ) 94:383–94.

    Not in our library10.1016/j.jsbmb.2004.12.046

  24. 24.

    Nicolaides NC Galata Z Kino T Chrousos GP Charmandari E. The human glucocorticoid receptor: molecular basis of biologic function. Steroids (2010 ) 75:1–12.

    Not in our library10.1016/j.steroids.2009.09.002

  25. 25.

    Vandevyver S Dejager L Libert C. On the trail of the glucocorticoid receptor: into the nucleus and back. Traffic (2012 ) 13:364–74.

    Not in our library10.1111/j.1600-0854.2011.01288.x

  26. 26.

    Kirschke E Goswami D Southworth D Griffin PR Agard DA. Glucocorticoid receptor function regulated by coordinated action of the Hsp90 and Hsp70 chaperone cycles. Cell (2014 ) 157:1685–97.

    Not in our library10.1016/j.cell.2014.04.038

  27. 27.

    Savory JG Hsu B Laquian IR Giffin W Reich T Haché RJ Discrimination between NL1- and NL2-mediated nuclear localization of the glucocorticoid receptor. Mol Cell Biol (1999 ) 19:1025–37.

    Not in our library10.1128/mcb.19.2.1025

  28. 28.

    Haché RJ Tse R Reich T Savory JG Lefebvre YA. Nucleocytoplasmic trafficking of steroid-free glucocorticoid receptor. J Biol Chem (1999 ) 274:1432–9.

    Not in our library10.1074/jbc.274.3.1432

  29. 29.

    Carrigan A Walther RF Salem HA Wu D Atlas E Lefebvre YA An active nuclear retention signal in the glucocorticoid receptor functions as a strong inducer of transcriptional activation. J Biol Chem (2007 ) 282:10963–71.

    Not in our library10.1074/jbc.m602931200

  30. 30.

    Robertson S Rohwer JM Hapgood JP Louw A. Impact of glucocorticoid receptor density on ligand-independent dimerization, cooperative ligand-binding and basal priming of transactivation: a cell culture model. PLoS One (2013 ) 8:e64831.

    Not in our library10.1371/journal.pone.0064831

  31. 31.

    Sanchez ER. Heat shock induces translocation to the nucleus of the unliganded glucocorticoid receptor. J Biol Chem (1992 ) 267:17–20.

    Not in our library

  32. 32.

    Robertson S Hapgood JP Louw A. Glucocorticoid receptor concentration and the ability to dimerize influence nuclear translocation and distribution. Steroids (2013 ) 78:182–94.

    Not in our library10.1016/j.steroids.2012.10.016

  33. 33.

    Oakley RH Cidlowski JA. The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease. J Allergy Clin Immunol (2013 ) 132:1033–44.

    Not in our library10.1016/j.jaci.2013.09.007

  34. 34.

    Davies TH Ning YM Sánchez ER. A new first step in activation of steroid receptors: hormone-induced switching of FKBP51 and FKBP52 immunophilins. J Biol Chem (2002 ) 277:4597–600.

    Not in our library10.1074/jbc.c100531200

  35. 35.

    Storer CL Dickey CA Galigniana MD Rein T Cox MB FKBP51 and FKBP52 in signaling and disease. Trends Endocrinol Metab (2011 ) 22:481–90.

    Not in our library10.1016/j.tem.2011.08.001

  36. 36.

    Echeverría PC Mazaira G Erlejman A Gomez-Sanchez C Piwien Pilipuk G Galigniana MD. Nuclear import of the glucocorticoid receptor-hsp90 complex through the nuclear pore complex is mediated by its interaction with Nup62 and importin beta. Mol Cell Biol (2009 ) 29:4788–97.

    Not in our library10.1128/mcb.00649-09

  37. 37.

    Galigniana MD Harrell JM O’Hagen HM Ljungman M Pratt WB. Hsp90-binding immunophilins link p53 to dynein during p53 transport to the nucleus. J Biol Chem (2004 ) 279:22483–9.

    Not in our library10.1074/jbc.m402223200

  38. 38.

    Bledsoe RK Montana VG Stanley TB Delves CJ Apolito CJ McKee DD Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell (2002 ) 110:93–105.

    Not in our library10.1016/s0092-8674(02)00817-6

  39. 39.
    Glucocorticoid receptor binds half sites as a monomer and regulates specific target genes · 2014
    No notice
  40. 40.

    Galigniana MD Echeverría PC Erlejman AG Piwien-Pilipuk G. Role of molecular chaperones and TPR-domain proteins in the cytoplasmic transport of steroid receptors and their passage through the nuclear pore. Nucleus (2010 ) 1:299–308.

    Not in our library10.4161/nucl.1.4.11743

  41. 41.

    Hakim A Barnes PJ Adcock IM Usmani OS. Importin-7 mediates glucocorticoid receptor nuclear import and is impaired by oxidative stress, leading to glucocorticoid insensitivity. FASEB J (2013 ) 27:4510–9.

    Not in our library10.1096/fj.12-222604

  42. 42.

    Hollenberg SM Weinberger C Ong ES Cerelli G Oro A Lebo R Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature (1985 ) 318:635–41.

    Not in our library10.1038/318635a0

  43. 43.

    Cole TJ Blendy JA Monaghan AP Krieglstein K Schmid W Aguzzi A Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation. Genes Dev (1995 ) 9:1608–21.

    Not in our library10.1101/gad.9.13.1608

  44. 44.

    Reichardt HM Umland T Bauer A Kretz O Schütz G. Mice with an increased glucocorticoid receptor gene dosage show enhanced resistance to stress and endotoxic shock. Mol Cell Biol (2000 ) 20:9009–17.

    Not in our library10.1128/mcb.20.23.9009-9017.2000

  45. 45.

    Opherk C Tronche F Kellendonk C Kohlmüller D Schulze A Schmid W Inactivation of the glucocorticoid receptor in hepatocytes leads to fasting hypoglycemia and ameliorates hyperglycemia in streptozotocin-induced diabetes mellitus. Mol Endocrinol (2004 ) 18:1346–53.

    Not in our library10.1210/me.2003-0283

  46. 46.

    Tronche F Opherk C Moriggl R Kellendonk C Reimann A Schwake L Glucocorticoid receptor function in hepatocytes is essential to promote postnatal body growth. Genes Dev (2004 ) 18:492–7.

    Not in our library10.1101/gad.284704

  47. 47.

    Boyle MP Kolber BJ Vogt SK Wozniak DF Muglia LJ. Forebrain glucocorticoid receptors modulate anxiety-associated locomotor activation and adrenal responsiveness. J Neurosci (2006 ) 26:1971–8.

    Not in our library10.1523/jneurosci.2173-05.2006

  48. 48.

    Bhattacharyya S Brown DE Brewer JA Vogt SK Muglia LJ. Macrophage glucocorticoid receptors regulate Toll-like receptor 4-mediated inflammatory responses by selective inhibition of p38 MAP kinase. Blood (2007 ) 109:4313–9.

    Not in our library10.1182/blood-2006-10-048215

  49. 49.

    Kleiman A Tuckermann JP. Glucocorticoid receptor action in beneficial and side effects of steroid therapy: lessons from conditional knockout mice. Mol Cell Endocrinol (2007 ) 275:98–108.

    Not in our library10.1016/j.mce.2007.05.009

  50. 50.

    Tuckermann JP Kleiman A Moriggl R Spanbroek R Neumann A Illing A Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy. J Clin Invest (2007 ) 117:1381–90.

    Not in our library10.1172/jci28034

  51. 51.

    Goodwin JE Feng Y Velazquez H Sessa WC. Endothelial glucocorticoid receptor is required for protection against sepsis. Proc Natl Acad Sci U S A (2013 ) 110(1):306–11.

    Not in our library10.1073/pnas.1210200110

  52. 52.

    Heck S Kullmann M Gast A Ponta H Rahmsdorf HJ Herrlich P A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1. EMBO J (1994 ) 13:4087–95.

    Not in our library10.1002/j.1460-2075.1994.tb06726.x

  53. 53.

    Lim HW Uhlenhaut NH Rauch A Weiner J Hübner S Hübner N Genomic redistribution of GR monomers and dimers mediates transcriptional response to exogenous glucocorticoid in vivo. Genome Res (2015 ) 25:836–44.

    Not in our library10.1101/gr.188581.114

  54. 54.

    Reichardt HM Kaestner KH Tuckermann J Kretz O Wessely O Bock R DNA binding of the glucocorticoid receptor is not essential for survival. Cell (1998 ) 93:531–41.

    Not in our library10.1016/s0092-8674(00)81183-6

  55. 55.

    Adcock IM Caramori G Ito K. New insights into the molecular mechanisms of corticosteroids actions. Curr Drug Targets (2006 ) 7:649–60.

    Not in our library10.2174/138945006777435344

  56. 56.
    Live Cell Imaging Unveils Multiple Domain Requirements for In Vivo Dimerization of the Glucocorticoid Receptor · 2014
    No notice
  57. 57.

    Kleiman A Hübner S Rodriguez Parkitna JM Neumann A Hofer S Weigand MA Glucocorticoid receptor dimerization is required for survival in septic shock via suppression of interleukin-1 in macrophages. FASEB J (2012 ) 26:722–9.

    Not in our library10.1096/fj.11-192112

  58. 58.

    Baschant U Frappart L Rauchhaus U Bruns L Reichardt HM Kamradt T Glucocorticoid therapy of antigen-induced arthritis depends on the dimerized glucocorticoid receptor in T cells. Proc Natl Acad Sci U S A (2011 ) 108:19317–22.

    Not in our library10.1073/pnas.1105857108

  59. 59.

    Wüst S van den Brandt J Tischner D Kleiman A Tuckermann JP Gold R Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis. J Immunol (2008 ) 180:8434–43.

    Not in our library10.4049/jimmunol.180.12.8434

  60. 60.

    Kugler DG Mittelstadt PR Ashwell JD Sher A Jankovic D. CD4+ T cells are trigger and target of the glucocorticoid response that prevents lethal immunopathology in toxoplasma infection. J Exp Med (2013 ) 210:1919–27.

    Not in our library10.1084/jem.20122300

  61. 61.

    Mittelstadt PR Monteiro JP Ashwell JD. Thymocyte responsiveness to endogenous glucocorticoids is required for immunological fitness. J Clin Invest (2012 ) 122:2384–94.

    Not in our library10.1172/jci63067

  62. 62.

    Revollo JR Cidlowski JA. Mechanisms generating diversity in glucocorticoid receptor signaling. Ann N Y Acad Sci (2009 ) 1179:167–78.

    Not in our library10.1111/j.1749-6632.2009.04986.x

  63. 63.

    Evans RM The steroid and thyroid hormone receptor superfamily. Science (1988 ) 240:889–95.

    Not in our library10.1126/science.3283939

  64. 64.

    Grøntved L John S Baek S Liu Y Buckley JR Vinson C C/EBP maintains chromatin accessibility in liver and facilitates glucocorticoid receptor recruitment to steroid response elements. EMBO J (2013 ) 32:1568–83.

    Not in our library10.1038/emboj.2013.106

  65. 65.

    Hapgood JP Avenant C Moliki JM. Glucocorticoid-independent modulation of GR activity: implications for immunotherapy. Pharmacol Ther (2016 ) 165:93–113.

    Not in our library10.1016/j.pharmthera.2016.06.002

  66. 66.

    Barnes PJ. Mechanisms and resistance in glucocorticoid control of inflammation. J Steroid Biochem Mol Biol (2010 ) 120:76–85.

    Not in our library10.1016/j.jsbmb.2010.02.018

  67. 67.

    Gronemeyer H Bourguet W. Allosteric effects govern nuclear receptor action: DNA appears as a player. Sci Signal (2009 ) 2:e34.

    Not in our library10.1126/scisignal.273pe34

  68. 68.

    Watson LC Kuchenbecker KM Schiller BJ Gross JD Pufall MA Yamamoto KR. The glucocorticoid receptor dimer interface allosterically transmits sequence-specific DNA signals. Nat Struct Mol Biol (2013 ) 20:876–83.

    Not in our library10.1038/nsmb.2595

  69. 69.

    Ratman D Vanden Berghe W Dejager L Libert C Tavernier J Beck IM How glucocorticoid receptors modulate the activity of other transcription factors: a scope beyond tethering. Mol Cell Endocrinol (2013 ) 380:41–54.

    Not in our library10.1016/j.mce.2012.12.014

  70. 70.

    Almawi WY Melemedjian OK. Molecular mechanisms of glucocorticoid antiproliferative effects: antagonism of transcription factor activity by glucocorticoid receptor. J Leukoc Biol (2002 ) 71:9–15.

    Not in our library

  71. 71.

    Lee HL Archer TK. Nucleosome-mediated disruption of transcription factor-chromatin initiation complexes at the mouse mammary tumor virus long terminal repeat in vivo. Mol Cell Biol (1994 ) 14:32–41.

    Not in our library10.1128/mcb.14.1.32

  72. 72.

    De Martino MU Bhattachryya N Alesci S Ichijo T Chrousos GP Kino T The glucocorticoid receptor and the orphan nuclear receptor chicken ovalbumin upstream promoter-transcription factor II interact with and mutually affect each other’s transcriptional activities: implications for intermediary metabolism. Mol Endocrinol (2004 ) 18:820–33.

    Not in our library10.1210/me.2003-0341

  73. 73.

    Biddie SC John S Sabo PJ Thurman RE Johnson TA Schiltz RL Transcription factor AP1 potentiates chromatin accessibility and glucocorticoid receptor binding. Mol Cell (2011 ) 43:145–55.

    Not in our library10.1016/j.molcel.2011.06.016

  74. 74.

    Patel R Patel M Tsai R Lin V Bookout AL Zhang Y LXRbeta is required for glucocorticoid-induced hyperglycemia and hepatosteatosis in mice. J Clin Invest (2011 ) 121:431–41.

    Not in our library10.1172/jci41681

  75. 75.

    Rao NA McCalman MT Moulos P Francoijs KJ Chatziioannou A Kolisis FN Coactivation of GR and NFKB alters the repertoire of their binding sites and target genes. Genome Res (2011 ) 21:1404–16.

    Not in our library10.1101/gr.118042.110

  76. 76.

    Siersbaek R Nielsen R John S Sung MH Baek S Loft A Extensive chromatin remodelling and establishment of transcription factor “hotspots” during early adipogenesis. EMBO J (2011 ) 30:1459–72.

    Not in our library10.1038/emboj.2011.65

  77. 77.

    Langlais D Couture C Balsalobre A Drouin J. The Stat3/GR interaction code: predictive value of direct/indirect DNA recruitment for transcription outcome. Mol Cell (2012 ) 47:38–49.

    Not in our library10.1016/j.molcel.2012.04.021

  78. 78.

    Surjit M Ganti KP Mukherji A Ye T Hua G Metzger D Widespread negative response elements mediate direct repression by agonist-liganded glucocorticoid receptor. Cell (2011 ) 145:224–41.

    Not in our library10.1016/j.cell.2011.03.027

  79. 79.

    Hudson WH Youn C Ortlund EA. The structural basis of direct glucocorticoid-mediated transrepression. Nat Struct Mol Biol (2013 ) 20:53–8.

    Not in our library10.1038/nsmb.2456

  80. 80.

    Clark AR Lasa M. Crosstalk between glucocorticoids and mitogen-activated protein kinase signalling pathways. Curr Opin Pharmacol (2003 ) 3:404–11.

    Not in our library10.1016/s1471-4892(03)00073-0

  81. 81.

    Ayroldi E Migliorati G Bruscoli S Marchetti C Zollo O Cannarile L Modulation of T-cell activation by the glucocorticoid-induced leucine zipper factor via inhibition of nuclear factor kappa-B. Blood (2001 ) 98:743–53.

    Not in our library10.1182/blood.v98.3.743

  82. 82.

    Pinheiro I Dejager L Petta I Vandevyver S Puimège L Mahieu T LPS resistance of SPRET/Ei mice is mediated by Gilz, encoded by the Tsc22d3 gene on the X chromosome. EMBO Mol Med (2013 ) 5:456–70.

    Not in our library10.1002/emmm.201201683

  83. 83.
    A mammalian pseudogene lncRNA at the interface of inflammation and anti-inflammatory therapeutics · 2013
    No notice
  84. 84.

    Reuter KC Grunwitz CR Kaminski BM Steinhilber D Radeke HH Stein J. Selective glucocorticoid receptor agonists for the treatment of inflammatory bowel disease: studies in mice with acute trinitrobenzene sulfonic acid colitis. J Pharmacol Exp Ther (2012 ) 341:68–80.

    Not in our library10.1124/jpet.111.183947

  85. 85.

    De Bosscher K Vanden Berghe W Beck IM Van Molle W Hennuyer N Hapgood J A fully dissociated compound of plant origin for inflammatory gene repression. Proc Natl Acad Sci U S A (2005 ) 102:15827–32.

    Not in our library10.1073/pnas.0505554102

  86. 86.

    Gossye V Elewaut D Van Beneden K Dewint P Haegeman G De Bosscher K. A plant-derived glucocorticoid receptor modulator attenuates inflammation without provoking ligand-induced resistance. Ann Rheum Dis (2010 ) 69:291–6.

    Not in our library10.1136/ard.2008.102871

  87. 87.

    Hua G Ganti KP Chambon P Glucocorticoid-induced tethered transrepression requires SUMOylation of GR and formation of a SUMO-SMRT/NCoR1-HDAC3 repressing complex. Proc Natl Acad Sci U S A (2015 ) 2015:201522821

    Not in our library10.1073/pnas.1522826113

  88. 88.

    Zalachoras I Houtman R Atucha E Devos R Tijssen AM Hu P Differential targeting of brain stress circuits with a selective glucocorticoid receptor modulator. Proc Natl Acad Sci U S A (2013 ) 110:7910–5.

    Not in our library10.1073/pnas.1219411110

  89. 89.

    Van Den Heuvel JK Boon MR Van Hengel I Peschier-Van Der Put E Van Beek L Van Harmelen V Identification of a selective glucocorticoid receptor modulator that prevents both diet-induced obesity and inflammation. Br J Pharmacol (2016 ) 173:1793–804.

    Not in our library10.1111/bph.13477

  90. 90.

    De Bosscher K Beck IM Ratman D Berghe WV Libert C. Activation of the glucocorticoid receptor in acute inflammation: the SEDIGRAM concept. Trends Pharmacol Sci (2016 ) 37:4–16.

    Not in our library10.1016/j.tips.2015.09.002

  91. 91.

    Chrousos GP Kino T. Intracellular glucocorticoid signaling: a formerly simple system turns stochastic. Sci STKE (2005 ) 2005:e48.

    Not in our library10.1126/stke.3042005pe48

  92. 92.

    Bamberger CM Bamberger AM De Castro M Chrousos GP. Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest (1995 ) 95:2435–41.

    Not in our library10.1172/jci117943

  93. 93.

    de Castro M Elliot S Kino T Bamberger C Karl M Webster E The non-ligand binding beta-isoform of the human glucocorticoid receptor (hGR beta): tissue levels, mechanism of action, and potential physiologic role. Mol Med (1996 ) 2:597–607.

    Not in our library

  94. 94.

    Fruchter O Kino T Zoumakis E Alesci S De Martino M Chrousos G The human glucocorticoid receptor (GR) isoform {beta} differentially suppresses GR{alpha}-induced transactivation stimulated by synthetic glucocorticoids. J Clin Endocrinol Metab (2005 ) 90:3505–9.

    Not in our library10.1210/jc.2004-1646

  95. 95.

    Kino T Manoli I Kelkar S Wang Y Su YA Chrousos GP. Glucocorticoid receptor (GR) beta has intrinsic, GRalpha-independent transcriptional activity. Biochem Biophys Res Commun (2009 ) 381:671–5.

    Not in our library10.1016/j.bbrc.2009.02.110

  96. 96.

    Marino JS Stechschulte LA Stec DE Nestor-Kalinoski A Coleman S Hinds TD Glucocorticoid receptor β induces hepatic steatosis by augmenting inflammation and inhibition of the peroxisome proliferator-activated receptor (PPAR) α. J Biol Chem (2016 ) 291:9383–94.

    Not in our library10.1074/jbc.m116.752311

  97. 97.

    Anbalagan M Huderson B Murphy L Rowan BG. Post-translational modifications of nuclear receptors and human disease. Nucl Recept Signal (2012 ) 10:1–13.

    Not in our library10.1621/nrs.10001

  98. 98.

    Duma D Silva-Santos JE Assreuy J. Inhibition of glucocorticoid receptor binding by nitric oxide in endotoxemic rats. Crit Care Med (2004 ) 32:2304–10.

    Not in our library10.1097/01.ccm.0000145996.57901

  99. 99.

    Galigniana MD Piwien-Pilipuk G Assreuy J Inhibition of glucocorticoid receptor binding by nitric oxide. Mol Pharmacol (1999 ) 55:317–23.

    Not in our library10.1124/mol.55.2.317

  100. 100.

    Colussi C Mozzetta C Gurtner A Illi B Rosati J Straino S HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc Natl Acad Sci U S A (2008 ) 105:19183–7.

    Not in our library10.1073/pnas.0805514105

  101. 101.

    Malhotra D Thimmulappa RK Mercado N Ito K Kombairaju P Kumar S Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients. J Clin Invest (2011 ) 121:4289–302.

    Not in our library10.1172/jci45144

  102. 102.

    Paul-Clark MJ Roviezzo F Flower RJ Cirino G Soldato PD Adcock IM Glucocorticoid receptor nitration leads to enhanced anti-inflammatory effects of novel steroid ligands. J Immunol (2003 ) 171:3245–52.

    Not in our library10.4049/jimmunol.171.6.3245

  103. 103.

    Ji JY Diamond SL. Exogenous nitric oxide activates the endothelial glucocorticoid receptor. Biochem Biophys Res Commun (2004 ) 318:192–7.

    Not in our library10.1016/j.bbrc.2004.04.008

  104. 104.

    Druker J Liberman AC Antunica-Noguerol M Gerez J Paez-Pereda M Rein T RSUME enhances glucocorticoid receptor SUMOylation and transcriptional activity. Mol Cell Biol (2013 ) 33:2116–27.

    Not in our library10.1128/mcb.01470-12

  105. 105.

    Hua G Paulen L Chambon P GR SUMOylation and formation of an SUMO-SMRT/NCoR1-HDAC3 repressing complex is mandatory for GC-induced IR nGRE-mediated transrepression. Proc Natl Acad Sci U S A (2016 ) 113:E626–34.

    Not in our library10.1073/pnas.1522821113

  106. 106.

    Kotitschke A Sadie-Van Gijsen H Avenant C Fernandes S Hapgood JP. Genomic and nongenomic cross talk between the gonadotropin-releasing hormone receptor and glucocorticoid receptor signaling pathways. Mol Endocrinol (2009 ) 23:1726–45.

    Not in our library10.1210/me.2008-0462

  107. 107.

    Matthews L Johnson J Berry A Trebble P Cookson A Spiller D Cell cycle phase regulates glucocorticoid receptor function. PLoS One (2011 ) 6:e22289.

    Not in our library10.1371/journal.pone.0022289

  108. 108.

    Verhoog NJ Du Toit A Avenant C Hapgood JP Glucocorticoid-independent repression of tumor necrosis factor (TNF) α-stimulated interleukin (IL)-6 expression by the glucocorticoid receptor: a potential mechanism for protection against an excessive inflammatory response. J Biol Chem (2011 ) 286:19297–310.

    Not in our library10.1074/jbc.m110.193672

  109. 109.

    Ritter HD Antonova L Mueller CR. The unliganded glucocorticoid receptor positively regulates the tumor suppressor gene BRCA1 through GABP beta. Mol Cancer Res (2012 ) 10:558–69.

    Not in our library10.1158/1541-7786.mcr-11-0423-t

  110. 110.

    Ritter HD Mueller CR. Expression microarray identifies the unliganded glucocorticoid receptor as a regulator of gene expression in mammary epithelial cells. BMC Cancer (2014 ) 14:275.

    Not in our library10.1186/1471-2407-14-275

  111. 111.

    Ji JY Jing H Diamond SL. Shear stress causes nuclear localization of endothelial glucocorticoid receptor and expression from the GRE promoter. Circ Res (2003 ) 92:279–85.

    Not in our library10.1161/01.res.0000057753.57106.0b

  112. 112.

    Vandevyver S Dejager L Van Bogaert T Kleyman A Liu Y Tuckermann J Glucocorticoid receptor dimerization induces MKP1 to protect against TNF-induced inflammation. J Clin Invest (2012 ) 122:2130–40.

    Not in our library10.1172/jci60006

  113. 113.

    Nayebosadri A Christopher L Ji JY. Bayesian image analysis of dexamethasone and shear stress-induced glucocorticoid receptor intracellular movement. Ann Biomed Eng (2012 ) 40:1508–19.

    Not in our library10.1007/s10439-011-0499-7

  114. 114.

    Nayebosadri A Ji JY Endothelial nuclear lamina is not required for glucocorticoid receptor nuclear import but does affect receptor-mediated transcription activation. Am J Physiol Cell Physiol (2013 ) 305:C309–22.

    Not in our library10.1152/ajpcell.00293.2012

  115. 115.

    Galliher-Beckley AJ Williams JG Cidlowski JA. Ligand-independent phosphorylation of the glucocorticoid receptor integrates cellular stress pathways with nuclear receptor signaling. Mol Cell Biol (2011 ) 31:4663–75.

    Not in our library10.1128/mcb.05866-11

  116. 116.

    Limbourg FP Liao JK Nontranscriptional actions of the glucocorticoid receptor. J Mol Med (Berl) (2003 ) 81:168–74.

    Not in our library10.1007/s00109-003-0418-y

  117. 117.

    Deng Q Riquelme D Trinh L Low MJ Tomic M Stojilkovic S Rapid glucocorticoid feedback inhibition of ACTH secretion involves ligand-dependent membrane association of glucocorticoid receptors. Endocrinology (2015 ) 156:3215–27.

    Not in our library10.1210/en.2015-1265

  118. 118.

    Strehl C Buttgereit F. Unraveling the functions of the membrane-bound glucocorticoid receptors: first clues on origin and functional activity. Ann N Y Acad Sci (2014 ) 1318:1–6.

    Not in our library10.1111/nyas.12364

  119. 119.

    Morgan DJ Poolman TM Williamson AJ Wang Z Clark NR Ma’ayan A Glucocorticoid receptor isoforms direct distinct mitochondrial programs to regulate ATP production. Sci Rep (2016 ) 6:26419.

    Not in our library10.1038/srep26419

  120. 120.

    Norman AW Mizwicki MT Norman DP Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat Rev Drug Discov (2004 ) 3:27–41.

    Not in our library10.1038/nrd1283

  121. 121.

    Stahn C Löwenberg M Hommes DW Buttgereit F. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol (2007 ) 275:71–8.

    Not in our library10.1016/j.mce.2007.05.019

  122. 122.

    Scheller K Sekeris CE Krohne G Hock R Hansen IA Scheer U. Localization of glucocorticoid hormone receptors in mitochondria of human cells. Eur J Cell Biol (2000 ) 79:299–307.

    Not in our library10.1078/s0171-9335(04)70033-3

  123. 123.

    Gruber CJ Gruber DM Gruber IM Wieser F Huber JC. Anatomy of the estrogen response element. Trends Endocrinol Metab (2004 ) 15:73–8.

    Not in our library10.1016/j.tem.2004.01.008

  124. 124.

    Psarra AM Sekeris CE. Glucocorticoids induce mitochondrial gene transcription in HepG2 cells: role of the mitochondrial glucocorticoid receptor. Biochim Biophys Acta (2011 ) 1813:1814–21.

    Not in our library10.1016/j.bbamcr.2011.05.014

  125. 125.

    Mendes ES Pereira A Danta I Duncan RC Wanner A. Comparative bronchial vasoconstrictive efficacy of inhaled glucocorticosteroids. Eur Respir J (2003 ) 21:989–93.

    Not in our library10.1183/09031936.03.00072402

  126. 126.

    Fürst R Schroeder T Eilken HM Bubik MF Kiemer AK Zahler S MAPK phosphatase-1 represents a novel anti-inflammatory target of glucocorticoids in the human endothelium. FASEB J (2007 ) 21:74–80.

    Not in our library10.1096/fj.06-6752com

Cited by papers we hold 6

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.